THERAPEUTICS
Intensive glucose control increased mortality and did not prevent cardiovascular events in type 2 diabetes
| The first 150 words of the full text of this article appear below. |
R P Byington
Dr R P Byington, Wake Forest University School of Medicine, Winston-Salem, NC, USA; bbyingto@wfubmc.edu
STUDY DESIGN
randomised controlled trial (Action to Control Cardiovascular Risk in Diabetes [ACCORD]).
concealed.*
blinded (outcome adjudication committee and laboratory staff).*
STUDY QUESTION
77 centres in the USA and Canada.
10 251 patients 40–79 years of age (mean age 62 y, 61% men) who had type 2 diabetes, glycated haemoglobin concentration
7.5%, and cardiovascular disease or, if
55 years of age, risk factors for cardiovascular disease. Exclusion criteria included body mass index >45 kg/m2, serum creatinine concentration >132 mmol/l (1.5 mg/dl), and frequent or recent serious hypoglycaemia.
intensive glucose control to achieve a target glycated haemoglobin concentration <6.0% (n = 5128) or standard glucose control to achieve a target glycated haemoglobin concentration of 7.0–7.9% (n = 5123).
composite of cardiovascular events (non-fatal myocardial infarction or stroke, or death from cardiovascular causes). Secondary outcomes included death from
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
